WW International (NASDAQ:WW) executives outlined the company’s efforts to reposition its weight-management business around behavioral support, telehealth and GLP-1 medications, following a restructuring that substantially reduced its debt burden.
Speaking at Morgan Stanley’s healthcare conference, Chief Financial Officer Felicia DellaFortuna said the company reduced debt from approximately $1.6 billion to about $465 million through its restructuring, while cutting interest expense to roughly $50 million from about $100 million. She said the company now expects to be free-cash-flow positive this year, enabling reinvestment in its products and growth initiatives.
Behavioral and Clinical Businesses
The company has shifted the traditional meeting-based Core+ experience toward virtual programming, offering sessions related to emotional support, GLP-1 education, cooking and other topics. It has also introduced GLP-1 Success and menopause-focused programs within Core+.
Core+ subscriber counts have grown for three consecutive quarters, DellaFortuna said, an outcome she described as having occurred only once previously in the past 15 years. She said the trend indicates that consumers still value accountability and community, though they may prefer virtual access over in-person workshops.
WeightWatchers’ clinical business, Med+, provides telehealth access to clinicians who can prescribe GLP-1 medications and manage patients’ care. Chief Operating Officer Jon Volkmann said the service includes support for side effects, dose titration and insurance prior authorizations, along with access to the company’s behavioral programs, diet-tracking app and virtual workshops.
Clinical subscribers increased nearly 56% in the second quarter, according to DellaFortuna. The company expects clinical revenue to account for 25% to 30% of total revenue in 2026, compared with 10% in 2024.
Focus on GLP-1 Care and Awareness
Volkmann said WeightWatchers aims to differentiate Med+ from providers focused primarily on issuing prescriptions. He said patients receive unlimited access to their clinical team, can log side effects and can work with registered dietitians.
He cited the company’s digital GLP-1 Success program, saying 72% of participating members reported better management of medication side effects. DellaFortuna also said members who engage with the company’s protein-focused GLP-1 Success program have shown 29% more weight loss than those who do not engage with the program.
The company increased marketing investment in the first quarter of 2026 as it sought to raise awareness that it offers GLP-1 medications. DellaFortuna said WeightWatchers allocated about 40% to 45% of its anticipated annual marketing spending during the quarter, compared with roughly 30% to 35% in prior years.
While WeightWatchers has broad overall brand recognition, DellaFortuna said awareness that it offers GLP-1s has remained around 30%. The company is seeking to maintain a more consistent marketing presence, including through influencers and partnerships.
Partnerships and Acquisition Channels
Executives highlighted an expansion with Sam’s Club, under which Sam’s Club members can access WeightWatchers programs at discounted rates. Members who choose Med+ can have prescriptions filled through Sam’s Club Pharmacy. Volkmann said the partnership also provides opportunities for digital outreach as well as in-person engagement by WeightWatchers coaches, dietitians and clinicians.
WeightWatchers has also worked to diversify member acquisition beyond direct-to-consumer marketing. Volkmann said its business-to-business offering, though still relatively small, can bring in clinical members through employers seeking supported GLP-1 care. The company also became a preferred telehealth prescriber on LillyDirect during the first half of the year.
In the behavioral segment, DellaFortuna acknowledged continued competitive pressure from do-it-yourself nutrition tools and artificial intelligence. She said the company has updated its technology by adding AI-powered food-photo recognition, voice tracking and barcode scanning to its app.
She said the company’s Points system remains a key differentiator because it is based on scientific research rather than solely on calorie counting.
Margins, Debt and Outlook
DellaFortuna said WeightWatchers has maintained adjusted gross margins near 73% despite operating products with different cost structures, including the clinician-intensive Med+ business. The company expects adjusted gross margin to remain above 72% this year.
For 2026, WeightWatchers guided for revenue of $620 million to $635 million and adjusted EBITDA of $105 million to $115 million. DellaFortuna said debt had been reduced further to just above $400 million after a prepayment and tender transaction, while its second-quarter cash balance was slightly above $100 million.
The company recently announced a new chief executive officer. DellaFortuna said the new leader brings operational and subscription-growth experience that could help accelerate the strategy already put in place.
About WW International (NASDAQ:WW)
WW International, formerly known as Weight Watchers International, is a global wellness company focused on weight management, healthy living and behavior change. The company provides personalized programs designed to help members improve nutrition, physical activity and other lifestyle habits through digital tools, guidance and community support.
Its offerings have historically included subscription-based access to a points-based food and activity program, mobile applications, meal and recipe resources, educational content, virtual coaching and in-person workshops.
